SCHEMBL770920

SCHEMBL770920

O=C(NCCC(=O)N1CCCC2CCCCC21)c1cc2ccccc2o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.54
SLC6A2 P23975 1/20 0.51
SLC6A4 P31645 1/20 0.51
MMP13 P45452 1/20 0.50
DRD3 P35462 3/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
HTR1A P08908 2/20 0.48
HTR2A P28223 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772325 0.80 RAB9A (0.53) RAB9ASMN1; SMN2HPGDALDH1A1NPC1
SCHEMBL770799 0.79 DPP4 (0.60) RAB9ASMN1; SMN2ALDH1A1HTTNPC1
SCHEMBL770258 0.78 PREP (0.57) RAB9ASMN1; SMN2HPGDPOLBNPC1
SCHEMBL770599 0.78 DRD3 (0.48) DRD3HDAC1HDAC2HDAC3HTR1A
SCHEMBL770850 0.77 HDAC1 (0.51) RAB9ADRD3HDAC1HDAC2HDAC3
SCHEMBL769803 0.76 HSD11B1 (0.46) RAB9ADRD3SMN1; SMN2HPGDALDH1A1
SCHEMBL769774 0.76 SLC6A4 (0.51) RAB9ASLC6A2SLC6A4DRD3HTR1A
SCHEMBL771034 0.76 PREP (0.59) DRD3HDAC1HDAC2HDAC3HTR1A
SCHEMBL770259 0.75 HSD11B1 (0.59) RAB9ASMN1; SMN2HPGDALDH1A1MEN1
SCHEMBL770966 0.75 RAB9A (0.51) RAB9ADRD3SMN1; SMN2NPC1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2187/4885SLC6A2 1521/4885SLC6A4 1747/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 RAB9A 2217/4885SLC6A2 1544/4885SLC6A4 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.